Skip to main content

Anika Therapeutics Value Stock - Dividend - Research Selection

Anika therapeutics

ISIN: US0352551081 , WKN: 889120

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company\'s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%?

2025-12-03
Key Insights Using the 2 Stage Free Cash Flow to Equity, Anika Therapeutics fair value estimate is US$15.45 Anika...

Anika Therapeutics Inc (ANIK) Q3 2025 Earnings Call Highlights: Strong Growth in Regenerative ...

2025-11-06
Anika Therapeutics Inc (ANIK) reports robust growth in regenerative solutions and cash flow, despite challenges in OEM channel revenue and gross margin pressures.

Anika Therapeutics (ANIK) Trades Below Fair Value; Valuation Discount Reinforces Cautious Market Narratives

2025-11-06
Anika Therapeutics (ANIK) remains unprofitable, but its revenue is forecast to grow at 4.7% per year, trailing the broader US market’s projected growth of 10.5%. While recent profit growth has not accelerated, the company has steadily reduced its losses over the past five years at an average annual rate of 6.5%. Investors are watching closely as Anika’s shares now trade at a significant discount to estimated fair value, with valuation metrics that compare favorably to industry peers. See our...

Anika (ANIK) Q3 2025 Earnings Call Transcript

2025-11-05
Need a quote from a Motley Fool analyst? Dr. Cheryl Renee Blanchard, President and Chief Executive Officer, and Stephen D. Griffin, Executive Vice President, Chief Financial Officer, and Chief Operating Officer, who will present our third quarter 2025 financial results and business highlights.

Anika Therapeutics (ANIK) Q3 Earnings and Revenues Top Estimates

2025-11-05
Anika (ANIK) delivered earnings and revenue surprises of +100.00% and +0.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript

2025-11-05
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call November 5, 2025 8:30 AM ESTCompany ParticipantsMatt HallCheryl Blanchard - President, CEO &...

Anika Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation

2025-11-05
2025-11-05. The following slide deck was published by Anika Therapeutics, Inc.

Anika: Q3 Earnings Snapshot

2025-11-05
BEDFORD, Mass. AP) — Anika Therapeutics Inc. ANIK) on Wednesday reported a loss of $2.3 million in its third quarter.

Anika Reports Third Quarter 2025 Financial Results

2025-11-05
Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.

Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study

2025-11-05
BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTR